Results for inhibitornih translation from Slovenian to English

pojav inhibitornih protiteles
development of inhibitory antibodies

preskusno gojišče za odkrivanje inhibitornih snovi
test medium for the detection of inhibitory substances

posneto mleko v prahu ne vsebuje inhibitornih snovi.
skimmed milk powder shall be free from inhibitory substances.

podatki o minimalnih inhibitornih koncentracijah za različne izolate candida so omejeni.
data were limited on the minimum inhibitory concentrations for different candida isolates.

o pojavu inhibitornih protiteles pri večkratnem jemanju zdravila obizur je malo kliničnih informacij.
there is a lack of clinical information on the development of inhibitory antibodies to obizur following repeated administration.

priporočljivo je, da zdravljenje temelji na klinični presoji in ne na detektiranju inhibitornih protiteles s testom bethesda.
it is recommended that treatment should be based on clinical judgement and not based on detection of inhibitory antibodies by the bethesda assay.

uporabi se deionizirana ali destilirana voda brez inhibitornih koncentracij strupenih snovi (npr. ionov cu++).
deionised or distilled water, free from inhibitory concentrations of toxic substances (e.g. cu ++ ions) is used.

to bi bilo treba preveriti s primerjalnimi preskusi z uporabo posnetega mleka v prahu, za katerega je znano, da ne vsebuje inhibitornih snovi.
this should be verified by comparative tests using a skimmed milk powder known to be free from inhibitory substances.

pri preskušanju petih glavnih izoencimov citokroma p450 (cyp1a, cyp2c9, cyp2c19, cyp2d6 in cyp3a4) niso odkrili inhibitornih učinkov deksrazoksana nanje.
cyp1a, cyp2c9, cyp2c19, cyp2d6 and cyp3a4, none of these were inhibited by dexrazoxane.

ipilimumab je zaviralec ctla-4 (“ctla-4 immune checkpoint inhibitor”), ki z zavrtjem t-celičnih inhibitornih signalov, ki se sprožijo preko ctla-4, poveča število reaktivnih efektorskih celic t, kar mobilizira neposredni t-celični imunski odziv proti tumorskim celicam.
ipilimumab is a ctla-4 immune checkpoint inhibitor that blocks t-cell inhibitory signals induced by the ctla-4 pathway, increasing the number of reactive t-effector cells which mobilize to mount a direct t-cell immune attack against tumour cells.